Abstract 52P
Background
The majority of colorectal cancers (CRCs), lung carcinomas (LCs) and melanomas contain hot-spot mutations in driver genes. This study evaluated the feasibility of disease monitoring using individual single-mutation tests for the analysis of circulating tumor DNA (ctDNA) in plasma.
Methods
The study included 49 patients with KRAS/BRAF-mutated CRC, EGFR-mutated LC, or BRAF-mutated melanoma, who received systemic treatment for metastatic disease. Blood samples were collected every 25-30 days; the number of time points varied from 2 to 12 for each patient with the individual follow-up ranging from 29 to 523 days (mean 208.7 ± 18.16). A total of 242 plasma samples were analyzed by droplet digital PCR to quantify ctDNA fragments carrying the corresponding driver mutation.
Results
In 25 patients (49%) no circulating mutant copies were detected in any of the serial samples; 24/25 (96%) of these ctDNA-negative subjects experienced either the reduction of tumor lumps or stable disease during the entire observation period. Twenty-four patients showed variations in the ctDNA status during the disease course. In 21/24 (88%) of these patients, the changes in the concentration of mutated ctDNA closely followed the dynamics of tumor volume as observed by computed tomography (CT). There were instances in which tumor progression was detected by liquid biopsy earlier than by imaging tools. One LC patient demonstrated an emergence of EGFR T790M mutation in the blood 126 days prior to tumor progression as registered by CT; in two other cases, the tumor growth was radiologically documented 23 and 34 days after the appearance of mutated ctDNA in plasma.
Conclusions
Serial ddPCR-based assessment of single driver mutations in ctDNA allows efficient monitoring of the efficacy of therapy in diverse categories of cancer patients. This work has been supported by the Russian Science Foundation grant #17-75-30027.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation grant #17-75-30027.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73P - Effect of combination therapy with atezolizumab plus metformin on peripheral immune cells from NSCLC patients
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis
Presenter: Lysanne Desharnais
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Possible significance of the proline at position 325 in the recognition of the MX35 epitope of the NaPi2b transporter by monoclonal antibodies
Presenter: Leisan Bulatova
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression
Presenter: Simon Milette
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Daily rhythmic expression of pro-tumoral programs in NSCLC shape cancer immunity and therapy response
Presenter: Alba de Juan
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter: Lodovica Zullo
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Single-cell spatial landscape of NSCLC reveals subtype specific immune features
Presenter: Mark Sorin
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation
Presenter: XIAOHE ZHOU
Session: Cocktail & Poster Display session
Resources:
Abstract
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract